Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Cost analysis of rapid diagnostics for drug-resistant tuberculosis.

Groessl EJ, Ganiats TG, Hillery N, Trollip A, Jackson RL, Catanzaro DG, Rodwell TC, Garfein RS, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

BMC Infect Dis. 2018 Mar 2;18(1):102. doi: 10.1186/s12879-018-3013-0.

2.

Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis.

Georghiou SB, Seifert M, Lin SY, Catanzaro D, Garfein RS, Jackson RL, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC.

BMC Infect Dis. 2016 Aug 31;16:458. doi: 10.1186/s12879-016-1781-y.

3.

Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3994-4004. doi: 10.1128/AAC.00222-16. Print 2016 Jul.

4.

A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis.

Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC.

Int J Tuberc Lung Dis. 2016 May;20(5):631-7. doi: 10.5588/ijtld.15.0788.

5.

Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value.

Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):621-30. doi: 10.1164/rccm.201510-2091OC.

6.

MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.

Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC.

J Clin Microbiol. 2016 Apr;54(4):912-8. doi: 10.1128/JCM.02505-15. Epub 2016 Jan 13.

7.

Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates.

Black PA, de Vos M, Louw GE, van der Merwe RG, Dippenaar A, Streicher EM, Abdallah AM, Sampson SL, Victor TC, Dolby T, Simpson JA, van Helden PD, Warren RM, Pain A.

BMC Genomics. 2015 Oct 24;16:857. doi: 10.1186/s12864-015-2067-2.

8.

Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy.

Pule CM, Sampson SL, Warren RM, Black PA, van Helden PD, Victor TC, Louw GE.

J Antimicrob Chemother. 2016 Jan;71(1):17-26. doi: 10.1093/jac/dkv316. Epub 2015 Oct 15. Review.

PMID:
26472768
9.

Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

ElMaraachli W, Slater M, Berrada ZL, Lin SY, Catanzaro A, Desmond E, Rodrigues C, Victor TC, Crudu V, Gler MT, Rodwell TC.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1222-6. doi: 10.5588/ijtld.14.0936.

10.

Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa.

Streicher EM, Sampson SL, Dheda K, Dolby T, Simpson JA, Victor TC, Gey van Pittius NC, van Helden PD, Warren RM.

J Clin Microbiol. 2015 Nov;53(11):3650-3. doi: 10.1128/JCM.01414-15. Epub 2015 Sep 2.

11.

Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis.

Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K.

PLoS One. 2015 Aug 31;10(8):e0136861. doi: 10.1371/journal.pone.0136861. eCollection 2015.

12.

Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.

Torres JN, Paul LV, Rodwell TC, Victor TC, Amallraja AM, Elghraoui A, Goodmanson AP, Ramirez-Busby SM, Chawla A, Zadorozhny V, Streicher EM, Sirgel FA, Catanzaro D, Rodrigues C, Gler MT, Crudu V, Catanzaro A, Valafar F.

Emerg Microbes Infect. 2015 Jul;4(7):e42. doi: 10.1038/emi.2015.42. Epub 2015 Jul 15.

13.

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks.

Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD.

PLoS One. 2015 Jul 21;10(7):e0134190. doi: 10.1371/journal.pone.0134190. eCollection 2015. No abstract available.

14.

Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.

Garfein RS, Catanzaro DG, Rodwell TC, Avalos E, Jackson RL, Kaping J, Evasco H, Rodrigues C, Crudu V, Lin SY, Groessl E, Hillery N, Trollip A, Ganiats T, Victor TC, Eisenach K, Valafar F, Channick J, Qian L, Catanzaro A.

Int J Tuberc Lung Dis. 2015 Apr;19(4):420-7. doi: 10.5588/ijtld.14.0488. Erratum in: Int J Tuberc Lung Dis. 2015 Jul;19(7):874. Groessel, E [corrected to Groessl, E].

15.

Prognostic significance of novel katG mutations in Mycobacterium tuberculosis.

Valafar F, Ramirez-Busby SM, Torres J, Paul LV, Rodwell TC, Victor TC, Rodrigues C, Gler MT, Crudu V, Catanzaro T.

Int J Mycobacteriol. 2015 Mar;4(Suppl 1):51-52. Epub 2015 Jan 7.

16.

The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis.

Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

Trials. 2014 Nov 6;15:434. doi: 10.1186/1745-6215-15-434.

17.

Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.

Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, Jackson L, Garfein RS, Catanzaro D, Eisenach K, Victor TC, Crudu V, Gler MT, Ismail N, Desmond E, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2015 Jan;59(1):414-20. doi: 10.1128/AAC.03614-14. Epub 2014 Nov 3.

18.

Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD.

Antimicrob Agents Chemother. 2014 May;58(5):2491-503. doi: 10.1128/AAC.02293-13. Epub 2014 Mar 10. Review.

19.

Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis.

Borrell S, Teo Y, Giardina F, Streicher EM, Klopper M, Feldmann J, Müller B, Victor TC, Gagneux S.

Evol Med Public Health. 2013 Jan;2013(1):65-74. doi: 10.1093/emph/eot003. Epub 2013 Mar 8.

20.

Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens.

Lin SY, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP.

J Clin Microbiol. 2014 Feb;52(2):475-82. doi: 10.1128/JCM.01821-13. Epub 2013 Nov 27.

21.

Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.

Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A.

J Clin Microbiol. 2014 Mar;52(3):781-9. doi: 10.1128/JCM.02701-13. Epub 2013 Dec 18.

22.

Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study.

Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR.

PLoS One. 2013 Dec 13;8(12):e83480. doi: 10.1371/journal.pone.0083480. eCollection 2013.

23.

Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape.

Shanley CA, Streicher EM, Warren RM, Victor TC, Orme IM.

Vaccine. 2013 Dec 5;31(50):5934-9. doi: 10.1016/j.vaccine.2013.10.044. Epub 2013 Oct 19.

24.

Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa.

Müller B, Chihota VN, Pillay M, Klopper M, Streicher EM, Coetzee G, Trollip A, Hayes C, Bosman ME, Gey van Pittius NC, Victor TC, Gagneux S, van Helden PD, Warren RM.

PLoS One. 2013 Aug 23;8(8):e70919. doi: 10.1371/journal.pone.0070919. eCollection 2013.

25.

Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis.

Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M.

Nat Genet. 2013 Oct;45(10):1183-9. doi: 10.1038/ng.2747. Epub 2013 Sep 1.

26.

Population structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent.

Hanekom M, Streicher EM, Van de Berg D, Cox H, McDermid C, Bosman M, Gey van Pittius NC, Victor TC, Kidd M, van Soolingen D, van Helden PD, Warren RM.

PLoS One. 2013 Jul 30;8(7):e70178. doi: 10.1371/journal.pone.0070178. Print 2013.

27.

Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa.

Shean K, Streicher E, Pieterson E, Symons G, van Zyl Smit R, Theron G, Lehloenya R, Padanilam X, Wilcox P, Victor TC, van Helden P, Grobusch MP, Warren R, Badri M, Dheda K.

PLoS One. 2013 May 7;8(5):e63057. doi: 10.1371/journal.pone.0063057. Print 2013. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/644591a8-8ae6-450e-974e-1cd1f08f52c7. Groubusch, Martin [corrected to Grobusch, Martin P].

28.

Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa.

Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Müller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, David van Helden P, Victor TC, Trollip AP.

Emerg Infect Dis. 2013 Mar;19(3):449-55. doi: 10.3201/EID1903.120246.

29.

Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa.

Marais BJ, Mlambo CK, Rastogi N, Zozio T, Duse AG, Victor TC, Marais E, Warren RM.

J Clin Microbiol. 2013 Jun;51(6):1818-25. doi: 10.1128/JCM.00200-13. Epub 2013 Apr 3.

30.

The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.

Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD.

PLoS One. 2013;8(3):e59414. doi: 10.1371/journal.pone.0059414. Epub 2013 Mar 19. Erratum in: PLoS One. 2015;10(7):e0134190.

31.

Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission.

de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC.

Antimicrob Agents Chemother. 2013 Feb;57(2):827-32. doi: 10.1128/AAC.01541-12. Epub 2012 Dec 3.

32.

embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis.

Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC.

Chemotherapy. 2012;58(5):358-63. doi: 10.1159/000343474. Epub 2012 Nov 17.

33.

Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa.

Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, van Helden PD, Victor TC, Streicher EM, Murray MB, Warren RM.

Clin Infect Dis. 2013 Feb;56(4):503-8. doi: 10.1093/cid/cis920. Epub 2012 Oct 22.

34.

Discordant drug susceptibility for mycobacterium tuberculosis within families.

Seddon JA, Jordaan AM, Victor TC, Schaaf HS.

Pediatr Infect Dis J. 2012 Jul;31(7):783-5. doi: 10.1097/INF.0b013e3182567c20.

PMID:
22466320
35.

Impact of drug resistance on clinical outcome in children with tuberculous meningitis.

Seddon JA, Visser DH, Bartens M, Jordaan AM, Victor TC, van Furth AM, Schoeman JF, Schaaf HS.

Pediatr Infect Dis J. 2012 Jul;31(7):711-6. doi: 10.1097/INF.0b013e318253acf8.

PMID:
22411053
36.

gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC.

J Antimicrob Chemother. 2012 May;67(5):1088-93. doi: 10.1093/jac/dks033. Epub 2012 Feb 22.

37.

Independent large scale duplications in multiple M. tuberculosis lineages overlapping the same genomic region.

Weiner B, Gomez J, Victor TC, Warren RM, Sloutsky A, Plikaytis BB, Posey JE, van Helden PD, Gey van Pittius NC, Koehrsen M, Sisk P, Stolte C, White J, Gagneux S, Birren B, Hung D, Murray M, Galagan J.

PLoS One. 2012;7(2):e26038. doi: 10.1371/journal.pone.0026038. Epub 2012 Feb 7.

38.

Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.

Streicher EM, Bergval I, Dheda K, Böttger EC, Gey van Pittius NC, Bosman M, Coetzee G, Anthony RM, van Helden PD, Victor TC, Warren RM.

Antimicrob Agents Chemother. 2012 May;56(5):2420-7. doi: 10.1128/AAC.05905-11. Epub 2012 Feb 13.

39.

Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Feb;16(2):196-202. doi: 10.5588/ijtld.11.0116.

40.

High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial.

Hesseling AC, Kim S, Madhi S, Nachman S, Schaaf HS, Violari A, Victor TC, McSherry G, Mitchell C, Cotton MF; IMPAACT P1041 Team.

Int J Tuberc Lung Dis. 2012 Feb;16(2):192-5. doi: 10.5588/ijtld.10.0795.

41.

Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.

Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Jan;16(1):76-81. doi: 10.5588/ijtld.11.0360.

42.

Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa.

Chihota VN, Müller B, Mlambo CK, Pillay M, Tait M, Streicher EM, Marais E, van der Spuy GD, Hanekom M, Coetzee G, Trollip A, Hayes C, Bosman ME, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM.

J Clin Microbiol. 2012 Mar;50(3):995-1002. doi: 10.1128/JCM.05832-11. Epub 2011 Dec 14.

43.

Detecting drug-resistant tuberculosis: the importance of rapid testing.

Hoek KG, Van Rie A, van Helden PD, Warren RM, Victor TC.

Mol Diagn Ther. 2011 Aug 1;15(4):189-94. doi: 10.2165/11593780-000000000-00000.

PMID:
21913741
44.

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.

Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, Trollip A, Hoek KG, Sirgel FA, Gey van Pittius NC, van Helden PD, Victor TC, Warren RM.

Infect Genet Evol. 2012 Jun;12(4):686-94. doi: 10.1016/j.meegid.2011.07.019. Epub 2011 Aug 4. Review.

PMID:
21839855
45.

Mycobacterium tuberculosis Beijing genotype: a template for success.

Hanekom M, Gey van Pittius NC, McEvoy C, Victor TC, Van Helden PD, Warren RM.

Tuberculosis (Edinb). 2011 Nov;91(6):510-23. doi: 10.1016/j.tube.2011.07.005. Epub 2011 Aug 10. Review.

PMID:
21835699
46.

Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.

Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB.

Clin Infect Dis. 2011 Aug;53(4):369-72. doi: 10.1093/cid/cir406.

47.

Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.

Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A.

Microb Drug Resist. 2012 Apr;18(2):193-7. doi: 10.1089/mdr.2011.0063. Epub 2011 Jul 6.

48.

Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and Beijing/W family of Mycobacterium tuberculosis.

Carugati M, Zanini F, Schiroli C, Gori A, Franzetti F, Hanekom M, van der Spuy GD, Gey van Pittius NC, McEvoy CR, Ndabambi SL, Victor TC, Hoal EG, van Helden PD, Warren RM.

J Clin Microbiol. 2011 Jul;49(7):2780; author reply 2781. doi: 10.1128/JCM.02089-09. No abstract available.

49.

Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC.

Am J Respir Crit Care Med. 2011 Jul 15;184(2):269-76. doi: 10.1164/rccm.201011-1924OC. Epub 2011 Apr 21.

50.

Tuberculosis assays: past, present and future.

Chegou NN, Hoek KG, Kriel M, Warren RM, Victor TC, Walzl G.

Expert Rev Anti Infect Ther. 2011 Apr;9(4):457-69. doi: 10.1586/eri.11.23. Review.

PMID:
21504402

Supplemental Content

Loading ...
Support Center